Esperion Therapeutics Stock Fundamentals
| ESPR Stock | USD 2.13 0.04 1.91% |
Esperion Therapeutics fundamentals help investors to digest information that contributes to Esperion Therapeutics' financial success or failures. It also enables traders to predict the movement of Esperion Stock. The fundamental analysis module provides a way to measure Esperion Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Esperion Therapeutics stock.
At this time, Esperion Therapeutics' Interest Expense is relatively stable compared to the past year. As of 04/25/2024, Other Operating Expenses is likely to grow to about 285.5 M, while Gross Profit is likely to drop slightly above 69.3 M. Esperion | Select Account or Indicator |
Esperion Therapeutics Company Operating Margin Analysis
Esperion Therapeutics' Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Current Esperion Therapeutics Operating Margin | (1.31) % |
Most of Esperion Therapeutics' fundamental indicators, such as Operating Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Esperion Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
| Competition |
Esperion Pretax Profit Margin
Pretax Profit Margin |
|
Based on the recorded statements, Esperion Therapeutics has an Operating Margin of -1.3137%. This is 96.26% lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The operating margin for all United States stocks is 76.16% lower than that of the firm.
Esperion Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Esperion Therapeutics's current stock value. Our valuation model uses many indicators to compare Esperion Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Esperion Therapeutics competition to find correlations between indicators driving Esperion Therapeutics's intrinsic value. More Info.Esperion Therapeutics is rated # 5 in return on equity category among related companies. It is rated # 5 in return on asset category among related companies . At this time, Esperion Therapeutics' Return On Equity is relatively stable compared to the past year.Comparative valuation analysis is a catch-all model that can be used if you cannot value Esperion Therapeutics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Esperion Therapeutics' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Esperion Therapeutics' earnings, one of the primary drivers of an investment's value.Did you try this?
Run Odds Of Bankruptcy Now
Odds Of BankruptcyGet analysis of equity chance of financial distress in the next 2 years |
| All Next | Launch Module |
Esperion Fundamentals
| Return On Equity | -2.61 | ||||
| Return On Asset | -0.43 | ||||
| Profit Margin | (1.80) % | ||||
| Operating Margin | (1.31) % | ||||
| Current Valuation | 852.86 M | ||||
| Shares Outstanding | 189.4 M | ||||
| Shares Owned By Insiders | 0.45 % | ||||
| Shares Owned By Institutions | 39.20 % | ||||
| Number Of Shares Shorted | 18.6 M | ||||
| Price To Earning | (8.19) X | ||||
| Price To Book | 74.89 X | ||||
| Price To Sales | 3.40 X | ||||
| Revenue | 116.33 M | ||||
| Gross Profit | (70.42 M) | ||||
| EBITDA | (155.4 M) | ||||
| Net Income | (209.25 M) | ||||
| Cash And Equivalents | 185.84 M | ||||
| Cash Per Share | 2.79 X | ||||
| Total Debt | 540.95 M | ||||
| Current Ratio | 3.07 X | ||||
| Book Value Per Share | (3.85) X | ||||
| Cash Flow From Operations | (135.49 M) | ||||
| Short Ratio | 1.95 X | ||||
| Earnings Per Share | (2.03) X | ||||
| Price To Earnings To Growth | (4.78) X | ||||
| Target Price | 7.41 | ||||
| Number Of Employees | 240 | ||||
| Beta | 0.82 | ||||
| Market Capitalization | 403.42 M | ||||
| Total Asset | 205.8 M | ||||
| Retained Earnings | (1.55 B) | ||||
| Working Capital | 44.84 M | ||||
| Current Asset | 214.39 M | ||||
| Current Liabilities | 5.62 M | ||||
| Net Asset | 205.8 M |
About Esperion Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Esperion Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Esperion Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Esperion Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 25.4 M | 26.7 M | |
| Cost Of Revenue | 43.4 M | 49.3 M | |
| Total Revenue | 116.3 M | 110.5 M | |
| Stock Based Compensation To Revenue | 0.10 | 0.12 | |
| Sales General And Administrative To Revenue | 1.09 | 0.69 | |
| Research And Ddevelopement To Revenue | 0.74 | 0.70 | |
| Capex To Revenue | (0.05) | (0.06) | |
| Revenue Per Share | 1.13 | 1.07 | |
| Ebit Per Revenue | (1.34) | (1.40) |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Esperion Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Esperion Therapeutics' short interest history, or implied volatility extrapolated from Esperion Therapeutics options trading.
Pair Trading with Esperion Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Esperion Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Esperion Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Esperion Stock
| 0.5 | ELYM | Eliem Therapeutics | PairCorr |
The ability to find closely correlated positions to Esperion Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Esperion Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Esperion Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Esperion Therapeutics to buy it.
The correlation of Esperion Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Esperion Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Esperion Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Esperion Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Esperion Therapeutics Piotroski F Score and Esperion Therapeutics Altman Z Score analysis. To learn how to invest in Esperion Stock, please use our How to Invest in Esperion Therapeutics guide.You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Complementary Tools for Esperion Stock analysis
When running Esperion Therapeutics' price analysis, check to measure Esperion Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Esperion Therapeutics is operating at the current time. Most of Esperion Therapeutics' value examination focuses on studying past and present price action to predict the probability of Esperion Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Esperion Therapeutics' price. Additionally, you may evaluate how the addition of Esperion Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios |
Is Esperion Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Esperion Therapeutics. If investors know Esperion will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Esperion Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.03) | Revenue Per Share 1.128 | Quarterly Revenue Growth 0.714 | Return On Assets (0.43) | Return On Equity (2.61) |
The market value of Esperion Therapeutics is measured differently than its book value, which is the value of Esperion that is recorded on the company's balance sheet. Investors also form their own opinion of Esperion Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Esperion Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Esperion Therapeutics' market value can be influenced by many factors that don't directly affect Esperion Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Esperion Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Esperion Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Esperion Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.